FDA Approves Sorilux for Adolescent Plaque Psoriasis
The US Food and Drug Administration (FDA) has approved SORILUX (calcipotriene) Foam, 0.005% in adolescents.
The US Food and Drug Administration (FDA) has approved SORILUX (calcipotriene) Foam, 0.005% in adolescents.
The reusable handpiece is now commercially available as part of the body contouring platform, which combines fat removal, electrosurgery, and Renuvion tissue contraction technology.